News
Eli Lilly (NYSE:LLY) has agreed to acquire Boston-based gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B ...
Exactly 10 years ago Monday, Donald Trump descended an escalator and announced his run for president, a moment many now see ...
Thailand’s pharmaceutical industry continues to face multiple challenges, particularly its heavy reliance on imported active ...
Jyong Biotech Ltd. (the "Company"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative ...
Organon faces profitability challenges and revenue declines. The valuation appears fair given the weak revenue outlook. See ...
President Donald Trump’s executive order, which threatens pharmaceutical companies with targeted retaliation and lawsuits if ...
President Trump just issued an executive order to rebalance the global pharmaceutical market — by tying U.S. drug prices to ...
On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company. Novo Nordisk (NYSE: NVO) stock ...
On November 5, 2024, voters sent a clear message by electing Donald Trump. In the last five months, President Trump has delivered on the many promises he made t ...
AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...
President Trump just issued an executive order to rebalance the global pharmaceutical market -- by tying U.S. drug prices to the artificially low, government-set prices in other developed nations.
Administration officials have good intentions. They’re trying to shake up the plainly unacceptable status quo, in which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results